Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

9 Months Ended

Sep. 30, 2023

Note 10 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Accrued clinical and development expenditure	$	13,208	$	16,749
Accrued employee expenses		11,047		8,232
Other accrued expenditure		2,504		4,079
Other		72		2,155
	$	26,831	$	31,215